免疫检查点抑制剂在食管癌治疗中的研究进展  

Advances in the treatment of immune checkpoint inhibitors for esophageal cancer

作　　者：童欣 邢力刚[1] Tong Xin;Xing Ligang(Department of Radiation Oncology,Shandong Cancer Hospital Affiliated to Shandong First Medical University,Jinan 250117,China;Department of Radiation Oncology,Zibo Central Hospital,Zibo 255000,China)

机构地区：[1]山东第一医科大学附属山东省肿瘤医院放疗科,济南250117 [2]淄博市中心医院放疗科,淄博255000

出　　处：《中国医师杂志》2022年第1期142-145,共4页Journal of Chinese Physician

基　　金：国家自然科学基金(81572970);国家重点研发项目(2018YFC1313200)。

摘　　要：免疫治疗是一种新兴的食管癌治疗方法,且越来越受到人们的重视。已经完成的和正在进行中的食管癌免疫治疗临床试验均肯定了免疫检查点抑制剂在食管癌治疗中的巨大潜力。将免疫疗法与现有的或者新的治疗模式相结合,以及甄别可能从免疫治疗中获益的人群将是未来研究的重点。As a new therapeutic strategy for esophageal cancer,immunotherapy has attracted more and more attention.The completed and ongoing clinical trials of immunotherapy for esophageal cancer confirm the great potential of immune checkpoint inhibitors in esophageal cancer.Future research will focus on the combination of immunotherapy with existing or new therapeutic modalities and the identification of populations likely to benefit from immunotherapy.

关 键 词：食管肿瘤 免疫检查点抑制剂 生物标记 

分 类 号：R735.1[医药卫生—肿瘤]